AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06752616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral lorazepam
Description: Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs
Study NCT06753474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus influenza A H3N2 strain
Description: Live Influenza Virus RG-A/Texas/71/2017 (H3N2). It is a cell-grown, reverse genetics-derived influenza A virus manufactured to conduct clinical trials that involve controlled human infection with influenza A virus. This influenza human challenge virus was produced for the National Institute of Allergy and Infectious Diseases (NIAID).~The final Drug Product Live Influenza Virus RG-A/Texas/71/2017 (H3N2) (Lot #1507-232149) vial contains 1.86 X 106 median tissue culture infectious doses (TCID50)/mL formulated in 1X sucrose-phosphate-glutamate (SPG; 7.4% sucrose, 3.8 mM KH2PO4, 7.2 mM K2HPO4, 5.4 mM L-glutamic acid) in Ex-Cellä 293 serum-free medium (Sigma-Aldrich). It is susceptible to the FDA-approved neuraminidase (NA) inhibitors (NAI) oseltamivir phosphate, zanamivir, and peramivir, and the polymerase acidic (PA) inhibitor (PAI) baloxavir marboxil.x
Study NCT06755515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rulonilimab
Description: Drug: Rulonilimab Description: iv, 200mg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.
Study NCT06755515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.
Study NCT06755515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin/carboplatin + paclitaxel ± bevacizumab
Description: cisplatin/carboplatin + paclitaxel ± bevacizumab
Study NCT06755515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin + paclitaxel ± bevacizumab
Description: cisplatin/carboplatin + paclitaxel ± bevacizumab
Study NCT06752356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune globulin (human) 10% solution for intravenous administration
Description: Kedrion intravenous immunoglobulin (IVIg) 10%
Study NCT06751485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: Experimental drug
Study NCT06751485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Active Comparator
Study NCT06751485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Active Comparator
Study NCT06751485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Active Comparator
Study NCT06752252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided paravertebral block
Description: after sterilization and identifying the level of T10 ,linear ultrasound probe will be placed in the midline over the spinous process at the chosen level, then the probe will be moved laterally to view the lamina and hyperechoic transverse process ,the pleural should be visible as a bright white line .The needle should be inserted in -plane from lateral to medial and the needle tip should end in a hypoechoic triangular space. Correct needle placement should be confirmed by anterior displacement of pleura with injection of small volume of saline then 0.5 ml/kg of a mixture of 0.25 ℅ bupivacaine and 1℅ lidocaine (1:1) will be injected
Study NCT06752252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae plane block
Description: After sterilization, the linear ultrasound probe will be placed over transverse process of T10 ,after optimizing the image in sagittal or transverse scanning ,A 50 mm 22-G needle will be placed under the erector spinae muscle in -in plane orientation until it contacted T8 transverse process in the cranial caudal direction ,after hydro dissection and confirmation that the tip of the needle is between the transverse process and the fascia of the erector spinae muscle group, 0.5 ml/kg of a mixture of 0.25 ℅bupivacaine and 1℅ lidocaine (1:1) will be injected
Study NCT06752252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group C
Description: will receive standard general anesthesia with pain management protocol without regional block.
Study NCT06752135 — intervention group
Intervention type: PROCEDURE
Intervention: cervical biopsies/conization,
Description: Diagnostic laparoscopy was used in selected cases to evaluate potential peritoneal spread.
Study NCT06752135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: imaging tests (TCTB, TC-PET, MRI)
Description: The staging procedures included imaging such as chest CT, abdomino-pelvic MRI, and PET-CT to assess tumor spread and lymph node involvement.
Study NCT06752135 — intervention group
Intervention type: DRUG
Intervention: neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel)
Description: Patients received three cycles of platinum-based neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel), followed by imaging to assess treatment response.
Study NCT06752135 — intervention group
Intervention type: PROCEDURE
Intervention: hysterectomy, salpingo-oophorectomy, and lymphadenectomy
Description: Eligible patients underwent radical surgery, including hysterectomy, salpingo-oophorectomy, and lymphadenectomy, with adjuvant therapy administered as needed based on surgical findings. Follow-up included regular clinical exams, imaging, and tests to monitor for recurrence.
Study NCT06752135 — intervention group
Intervention type: RADIATION
Intervention: brachytherapy
Description: alternative to cCRT-B.
Study NCT06752564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Oriented Care Model
Description: The experimental group : Goal-Oriented Care (GOC) The concept of Goal-Oriented Care (GOC) was first introduced by Mold et al. in 1991, addressing the limitations of problem-oriented care, which focuses on eradicating diseases and preventing death. GOC is defined as a process of reaching a consensus on health-related goals between the healthcare team and the patient (Vermunt et al., 2017). It is based on patients' core values and priorities within a clinical context, guiding medical interventions and specific treatment decisions (Secunda et al., 2020).~Healthcare professionals using GOC aim to help patients achieve their maximum personal health potential, aligning care with individual goals. The clear direction provided by GOC fosters teamwork and interdisciplinary collaboration (Gray et al., 2020). When establishing long-term goals with patients, it is crucial to revisit and adjust these goals, considering realistic survival timelines, as time plays a vital role in goal-setting.
Study NCT06752564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard health education
Description: The control group received standard health education. The content of the standard health education included verbal instructions provided by nurses during the general hospital stay, as well as the distribution of educational pamphlets. These instructions covered topics such as the frequency of dialysis and dietary control. The standard health education was generic, without a specific schedule or structured content.
Study NCT06752564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard health education
Description: The control group received standard health education. The content of the standard health education included verbal instructions provided by nurses during the general hospital stay, as well as the distribution of educational pamphlets. These instructions covered topics such as the frequency of dialysis and dietary control. The standard health education was generic, without a specific schedule or structured content.
Study NCT06754293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation exercise
Description: The intervention group will participate in a home-based exercise program alongside standard rehabilitation guidance. Patients will receive exercise materials developed by the intervention team, along with a detailed explanation of the program, including its components, specific exercises, and expected benefits.~The exercise program focuses on aerobic warm-ups and functional training, targeting key areas such as the hands, arms, shoulders, hips, legs, and back. It is designed to meet the rehabilitation needs of breast cancer patients undergoing endocrine therapy after surgery, addressing their unique challenges and enhancing recovery.~The intervention team, composed of specialists in breast cancer treatment, rehabilitation therapists, nursing experts, and methodologists, has created a professional exercise guidance manual. This manual provides detailed descriptions of exercise types, specific methods, and safety precautions. To ensure effective implementation, instructional videos have
Study NCT06752031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSCAR-CTI Care Transition Model
Description: Patients and families in the intervention arm will receive touch points from the surgery nurse coach to support their care transition from hospital to home after surgery.
Study NCT06191848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Participants will receive tirzepatide subcutaneously
Study NCT06191848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo subcutaneously
Study NCT05137587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Pulmonary Index (IPI) monitoring
Description: Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
Study NCT05137587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol
Study NCT05137587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine
Study NCT04260776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2: re-engagement text messages
Description: In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
Study NCT05309304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin Injection - 2 g/100 mL or 3 g/150 mL
Study NCT05309304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin Injection - 2 g/100 mL or 3 g/150 mL
Study NCT05388253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Using Static Stretching exercises
Study NCT05388253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Kneading Massage
Description: Using Deep Kneading Massage technique
Study NCT04969523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lobectomy
Description: Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
Study NCT04969523 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lobectomy
Description: Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
Study NCT05787054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Third trimester ultrasound
Description: Single scan versus Longitudinal scan
Study NCT05787054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Third trimester ultrasound
Description: Single scan versus Longitudinal scan
Study NCT04958018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: almond (Prunus dulcis) consumption
Study NCT04958018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Snack bars
Description: 324 calories/day, Nutri-Grain cereal bars, 120 kcal each
Study NCT04260776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2: re-engagement emails
Description: In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
Study NCT05076955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin-tobramycin-itraconazole
Description: Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
Study NCT05079620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
Study NCT05974878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: * Joints targeted by exercise; bilateral wrist, metacarpophalangeal, proximal and distal interphalangeal joints, elbow and shoulder joints.~* The muscles targeted by the exercises; lumbricals, iinterosseals, thenar and hypothenar muscles, forearm flexors, forearm extensors, forearm supinators and pronators, elbow flexors and extensors, and shoulder girdle muscles.~* Content of the exercises; There will be warm-up exercises, pinch grip, full grip, nerve and tendon gliding exercises, exercises that improve proprioception, functional exercises, strengthening exercises and stretching exercises.
Study NCT05974878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: For control group there will be aerobic exercise recommendation and resistive exercises focused on upper extremity.
Study NCT05079620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanic acid
Description: At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
Study NCT05079620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime
Description: If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
Study NCT05079620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
Study NCT05079620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
Study NCT04943198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 20 mg/kg/day
Study NCT06416969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
Study NCT06416969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Intravenous infusion
Study NCT06385288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood and tissue collection for immunological studies, advanced imaging.
Description: Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
Study NCT06385288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neoadjuvant Therapy
Description: neoadjuvant Therapy
Study NCT06509477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.)
Description: Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
Study NCT06509477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)
Description: Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
Study NCT06055400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR-US
Description: The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
Study NCT05544747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: following phases will be included in action observation therapy group:~1. upper limb active range of motion (AROM) exercises.~2. reaching movement or object manipulation.~3. upper limb functional tasks.
Study NCT05544747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: following phases will be included in mirror therapy group:~1. AROM exercises),~2. reaching movement or object manipulation, and~3. functional task practice
Study NCT06535152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifelight
Description: Lifelight is a artificial-intelligence software application that enables completely contactless spot measurements (i.e., one-off measurements without prior calibration) of PR and BP. Based on the science of remote photoplethysmography (rPPG), Lifelight works by detecting tiny changes in the colour of facial skin that occur every time the heart beats. All that is required to generate PR and BP measurements is that the software application is downloaded onto a computer device (e.g., smartphone or tablet) with a standard camera, and that the patient's face stays in the line of sight of the camera for up to 60 seconds.
Study NCT06535152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual sphygmomanometer
Description: Blood Pressure Measurement
Study NCT06297018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bioenergy application
Description: Bioenergy application: This group includes liver transplant recipients and recipients who underwent intervention. Depression, anxiety and stress levels are measured in the pre-test. Bioenergy is then applied. As a post-test, depression, anxiety and stress levels are measured again.
Study NCT05129865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-300
Description: A prodrug of allopregnanolone, a small molecule drug
Study NCT05129865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LYT-300
Description: A prodrug of allopregnanolone, a small molecule drug
Study NCT05129865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for LYT-300
Study NCT05129865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for LYT-300
Study NCT05306730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECHOcardiography, Point-of-Care UZ
Description: Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
Study NCT04858776 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Perivascular dexamethasone
Description: Dexamethasone delivery around target vein segment(s)
Study NCT00057096 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: On-site vs. referral methods of care
Study NCT04858776 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Perivascular sham
Description: Saline delivery around target vein segment(s)
Study NCT05156658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel (ENG) Subdermal Implants
Description: Etonogestrel is available as a single, white/off-white, soft, radiopaque, flexible, ethylene vinyl acetate copolymer implant, 4 cm in length and 2 mm in diameter containing 68 mg of etonogestrel. Store at 25°C (77°F); excursions permitted between 15 and 30°C (59-86°F) \[see USP Controlled Room Temperature\]. Avoid storing ENG at temperatures above 30°C (86°F).
Study NCT05074628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin capsules
Description: methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.
Study NCT05074628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin capsules
Description: methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.